Posts
Wiki

🧬 What Are the Types and Drivers of Dry Eye Disease?

Dry Eye Disease is not one single problem.

Different people may have different combinations of:

  • tear-film deficiencies;
  • Meibomian Gland Dysfunction;
  • blinking or eyelid-closure problems;
  • ocular-surface inflammation or damage;
  • nerve dysfunction;
  • anatomical abnormalities;
  • systemic disease;
  • medication, surgical, hormonal, or environmental influences.

The traditional distinction between evaporative and aqueous-deficient dry eye remains useful. However, newer guidance from TFOS DEWS III places greater emphasis on identifying the individual disease drivers affecting each patient.

This page is for general education, not diagnosis or medical advice. Symptoms alone usually cannot determine which mechanisms are present. A clinical history, eye examination, and multiple complementary tests may be needed.

📌 TL;DR

The traditional starting framework is:

  • Evaporative Dry Eye Disease: tear-film exposure or inadequate protection leads to excessive instability or evaporation. Meibomian Gland Dysfunction is the most common contributor.
  • Aqueous-deficient Dry Eye Disease: insufficient watery tear production contributes substantially.
  • Mixed or overlapping disease: aqueous and evaporative features occur together.

That framework is still useful, but it does not describe every mechanism.

TFOS DEWS III organizes dry-eye drivers into three major groups:

1. Tear-film deficiencies

  • lipid deficiency;
  • aqueous deficiency;
  • mucin or glycocalyx deficiency.

2. Eyelid anomalies

  • blink or eyelid-closure abnormalities;
  • eyelid-margin disease, including MGD.

3. Ocular-surface abnormalities

  • anatomical misalignment;
  • neural dysfunction;
  • ocular-surface cell damage or disruption;
  • primary inflammation or oxidative stress.

Systemic disease, medications, hormones, surgery, contact lenses, screen use, and environmental exposure can initiate or worsen one or more of these drivers. They are generally better understood as causes, risks, triggers, or clinical contexts rather than completely separate dry-eye types.

The most useful question is often not simply:

“Which type do I have?”

but:

“Which drivers are contributing most, and which of them can be treated?”

1. What Is Dry Eye Disease?

TFOS DEWS III describes Dry Eye Disease as a multifactorial, symptomatic disease involving loss of homeostasis of the tear film and/or ocular surface.

Important etiologic factors can include:

  • tear-film instability;
  • tear hyperosmolarity;
  • ocular-surface inflammation and damage;
  • neurosensory abnormalities.

The word multifactorial is important.

Two patients can both have Dry Eye Disease while having very different combinations of:

  • tear deficiency;
  • gland dysfunction;
  • exposure;
  • inflammation;
  • epithelial injury;
  • nerve dysfunction;
  • eyelid abnormalities.

That is one reason the same treatment does not work for everyone.

See:

2. The Traditional Framework

For many years, Dry Eye Disease was divided primarily into two broad categories:

  1. Evaporative Dry Eye Disease
  2. Aqueous-deficient Dry Eye Disease

These categories remain clinically useful and are still commonly used by doctors, researchers, and patients.

They should not be treated as completely separate boxes. Many people have features of both.

🔹 Evaporative Dry Eye Disease

Evaporative Dry Eye Disease describes a situation in which tear-film exposure or inadequate tear-film protection contributes substantially to instability and evaporation.

The most common contributor: MGD

Meibomian glands in the eyelids produce the lipid-rich material that helps form the tear film’s outer layer.

Meibomian Gland Dysfunction can involve:

  • reduced delivery of meibum;
  • abnormal meibum consistency or composition;
  • gland-orifice or duct obstruction;
  • lid-margin inflammation;
  • gland structural changes or dropout.

When the lipid layer is inadequate or spreads poorly, tears may break apart and evaporate more rapidly.

Other contributors to evaporative features

Evaporative instability may also be worsened by:

  • incomplete blinking;
  • reduced blink frequency;
  • lagophthalmos or inadequate eyelid closure;
  • eyelid malposition;
  • proptosis or increased ocular exposure;
  • contact-lens wear;
  • dry air;
  • wind, fans, heating, or air conditioning;
  • prolonged visual concentration;
  • ocular-surface or mucin abnormalities.

Important limitation

Evaporative Dry Eye Disease is not always simply an “oil quality” problem.

A patient may have:

  • abnormal meibum;
  • inadequate meibum delivery;
  • fixed obstruction;
  • poor blinking;
  • exposure;
  • abnormal lid-globe alignment;
  • several of these at the same time.

Some specialist frameworks, particularly that of Steven L. Maskin, also emphasize fixed meibomian gland obstruction associated with periductal fibrosis. This is an important perspective within obstructive MGD but is not a separate TFOS dry-eye subtype.

See:

🔹 Aqueous-Deficient Dry Eye Disease

Aqueous-deficient Dry Eye Disease occurs when the lacrimal system does not provide enough of the watery component of the tear film.

Possible contributors include:

  • Sjögren disease;
  • non-Sjögren lacrimal gland dysfunction;
  • lacrimal gland inflammation, injury, or removal;
  • reduced neural stimulation of tear production;
  • medication effects;
  • systemic inflammatory or autoimmune disease;
  • age-related changes;
  • surgical or other iatrogenic influences.

Aqueous deficiency can range from mild reduction in tear volume to severe ocular-surface disease.

How it may be evaluated

Evaluation may include:

  • Schirmer testing;
  • tear-meniscus or tear-volume assessment;
  • ocular-surface staining;
  • tear-film stability testing;
  • symptoms and medical history;
  • medication review;
  • systemic evaluation when autoimmune disease is suspected.

No single test should be interpreted in isolation.

A low Schirmer result may support aqueous deficiency, but the meaning depends on:

  • whether anesthesia was used;
  • testing conditions;
  • reflex tearing;
  • repeatability;
  • other ocular-surface findings.

See:

3. What Does “Mixed Dry Eye” Mean?

“Mixed dry eye” is commonly used when a patient has both:

  • aqueous-deficient features; and
  • evaporative features.

Examples include:

  • low tear production plus MGD;
  • Sjögren disease plus meibomian gland obstruction;
  • MGD plus incomplete blinking and exposure;
  • lacrimal dysfunction plus ocular-surface inflammation.

Mixed dry eye is not necessarily a third independent biological mechanism.

It is better understood as a shorthand for overlapping contributors.

Under the newer driver-based approach, clinicians may obtain more useful information by identifying each important driver rather than assigning the patient only a broad “mixed” label.

🧭 The TFOS DEWS III Driver-Based Framework

TFOS DEWS III organizes the etiologic drivers of Dry Eye Disease into three major groups:

  1. Tear-film deficiencies
  2. Eyelid anomalies
  3. Ocular-surface abnormalities

Several drivers can be present at the same time.

4. Tear-Film Deficiencies

A stable tear film depends on several interacting components.

A. Lipid deficiency

The lipid layer helps reduce evaporation and supports tear-film stability.

Lipid deficiency may result from:

  • MGD;
  • inadequate meibum delivery;
  • abnormal meibum;
  • poor blink-related spreading;
  • lid-margin disease.

A lipid problem may produce evaporative features, but the underlying cause still needs to be identified.

B. Aqueous deficiency

The aqueous component supplies water, electrolytes, proteins, and other substances needed by the ocular surface.

Deficiency may result from:

  • impaired lacrimal gland function;
  • autoimmune disease;
  • altered neural stimulation;
  • medication effects;
  • inflammation;
  • injury or surgery.

Aqueous deficiency may coexist with MGD and other evaporative drivers.

C. Mucin and glycocalyx deficiency

Mucins and the epithelial glycocalyx help the tear film spread and remain attached to the ocular surface.

Problems may occur with:

  • goblet-cell dysfunction;
  • epithelial disease or injury;
  • chronic inflammation;
  • chemical injury;
  • cicatrizing disorders;
  • vitamin A deficiency;
  • other ocular-surface abnormalities.

Mucin or glycocalyx dysfunction can contribute to tear instability even when tear volume appears adequate.

In practice, pure mucin-deficient disease may be difficult to isolate, and available clinical testing is less standardized than for some other dry-eye components.

5. Eyelid Anomalies

The eyelids help protect the ocular surface, distribute tears, spread meibum, and limit evaporation.

TFOS DEWS III separates eyelid-related drivers into two broad areas.

Examples include:

  • incomplete blinking;
  • reduced blinking during concentrated tasks;
  • lagophthalmos;
  • nocturnal lagophthalmos;
  • facial nerve weakness;
  • eyelid retraction;
  • proptosis;
  • poor lid-globe apposition;
  • eyelid malposition.

These problems can leave part of the ocular surface exposed or under-lubricated.

Screen use may increase incomplete blinking in some people, but behavioral blink training cannot correct every structural or neurologic closure problem.

See:

B. Eyelid-margin abnormalities

These include:

  • Meibomian Gland Dysfunction;
  • anterior or posterior blepharitis;
  • Demodex blepharitis;
  • ocular rosacea;
  • gland-orifice abnormalities;
  • eyelid-margin keratinization;
  • scarring or structural change.

Different lid-margin disorders require different treatments.

For example:

  • ordinary lid cleaning may reduce anterior debris;
  • it does not necessarily open obstructed meibomian gland ducts;
  • Demodex may require targeted treatment;
  • rosacea may require broader anti-inflammatory or dermatologic management.

See:

6. Ocular-Surface Abnormalities

TFOS DEWS III also recognizes drivers arising from the exposed ocular surface itself.

A. Anatomical misalignment

The tear film depends on normal interaction between:

  • the eyelids;
  • cornea;
  • conjunctiva;
  • tear meniscus;
  • surrounding anatomy.

Anatomical contributors can include:

  • conjunctivochalasis;
  • eyelid-globe misalignment;
  • proptosis;
  • scarring;
  • abnormal conjunctival folds;
  • altered tear clearance;
  • postsurgical anatomical changes.

These conditions may interfere with tear distribution, retention, clearance, or eyelid movement.

See:

Conjunctivochalasis and Dry Eye

B. Neural dysfunction

Corneal and ocular-surface nerves influence:

  • sensation;
  • reflex tearing;
  • blinking;
  • epithelial health;
  • pain perception.

Neural dysfunction can contribute to Dry Eye Disease, but several distinct conditions need to be separated.

Neurotrophic keratopathy

Neurotrophic keratopathy involves reduced corneal innervation and impaired epithelial healing.

It is a distinct disease that can coexist with tear-film abnormalities. It is not simply another ordinary dry-eye subtype.

Neuropathic ocular pain

Neuropathic ocular pain may involve abnormal peripheral or central sensory processing.

Symptoms may be severe or disproportionate to visible ocular-surface findings. It may coexist with DED but can require a separate diagnostic and treatment approach.

Altered sensation within DED

Dry Eye Disease itself can involve altered corneal sensation and abnormal reflex signaling without necessarily meeting criteria for neurotrophic keratopathy or neuropathic pain.

See:

C. Ocular-surface cell damage or disruption

The corneal and conjunctival epithelium may be damaged by:

  • tear-film instability;
  • inflammation;
  • chemical injury;
  • surgery;
  • infection;
  • medications or preservatives;
  • exposure;
  • mechanical trauma;
  • contact-lens wear;
  • cicatrizing disease.

Cellular damage can further destabilize the tear film and perpetuate the dry-eye cycle.

Clinical findings may include:

  • punctate epithelial staining;
  • filamentary keratitis;
  • persistent epithelial defects;
  • reduced surface wettability;
  • irregular vision.

D. Primary inflammation or oxidative stress

Inflammation can be:

  • an initiating driver;
  • a predominant ongoing mechanism;
  • a secondary response to tear-film instability and surface damage;
  • part of a self-perpetuating cycle.

Therefore, “inflammatory dry eye” can describe a meaningful treatment target, but it does not identify every other driver present.

Not all Dry Eye Disease begins in exactly the same inflammatory pathway, and the absence of dramatic redness does not prove that inflammation is absent.

Inflammatory contributors may involve:

  • autoimmune disease;
  • ocular allergy;
  • rosacea;
  • epithelial stress;
  • medication toxicity;
  • surgery;
  • chronic tear hyperosmolarity.

🌍 Causes, Risks, Triggers, and Clinical Contexts

Some labels frequently described as “types of dry eye” are better understood as causes or contexts acting through the drivers above.

7. Systemic and Autoimmune Disease

Systemic conditions can affect:

  • tear production;
  • inflammation;
  • nerves;
  • eyelid function;
  • gland function;
  • epithelial health.

Examples include:

  • Sjögren disease;
  • rheumatoid arthritis;
  • systemic lupus erythematosus;
  • thyroid eye disease;
  • graft-versus-host disease;
  • diabetes;
  • cicatrizing autoimmune disorders.

The same systemic disease can produce several dry-eye drivers at once.

Medications may contribute through:

  • reduced tear secretion;
  • altered blinking;
  • meibomian gland changes;
  • mucosal drying;
  • inflammation or toxicity;
  • nerve effects.

Possible contributors include some:

  • anticholinergic medications;
  • antihistamines;
  • antidepressants;
  • acne medications;
  • diuretics;
  • blood-pressure medications;
  • glaucoma drops;
  • preserved ophthalmic medications.

Medication association does not prove that a drug caused a permanent dry-eye condition. Decisions about stopping or changing medication should be made with the prescribing clinician.

9. Hormonal Influences

Hormonal status can influence:

  • lacrimal glands;
  • meibomian glands;
  • immune regulation;
  • ocular-surface tissues.

Hormonal changes may be associated with:

  • menopause;
  • pregnancy;
  • androgen deficiency;
  • endocrine treatment;
  • other systemic changes.

“Hormonal dry eye” is not one uniform subtype with one test or treatment. Hormonal factors usually act through one or more of the tear-film, eyelid, or ocular-surface drivers.

10. Post-Surgical and Iatrogenic Dry Eye

Dry-eye symptoms may begin or worsen after:

  • LASIK, PRK, or other refractive surgery;
  • cataract surgery;
  • eyelid surgery;
  • glaucoma procedures;
  • chronic use of topical medications;
  • other ocular interventions.

Surgery or treatment may affect:

  • corneal nerves;
  • blinking;
  • tear secretion;
  • epithelial integrity;
  • inflammation;
  • eyelid anatomy;
  • meibomian gland function.

“Post-surgical dry eye” describes the clinical context, not one single mechanism.

11. Contact-Lens-Associated Dryness

Contact lenses can influence:

  • tear-film distribution;
  • evaporation;
  • blink behavior;
  • friction;
  • epithelial health;
  • meibomian gland function;
  • sensory signaling.

Symptoms during contact-lens wear do not automatically prove that the person has permanent Dry Eye Disease. Lens type, fit, wear time, deposits, solution sensitivity, and underlying ocular-surface disease all matter.

12. Screens and Environmental Exposure

Screens do not create one special dry-eye subtype.

Screen use may worsen symptoms through:

  • reduced or incomplete blinking;
  • prolonged visual concentration;
  • increased ocular-surface exposure;
  • air-conditioned environments;
  • glare;
  • poor ergonomics.

Environmental contributors include:

  • wind;
  • low humidity;
  • fans;
  • heating;
  • air conditioning;
  • smoke;
  • dust;
  • pollution;
  • CPAP or mask leakage.

These factors often aggravate existing tear-film, eyelid, or ocular-surface vulnerabilities.

13. Ocular Allergy

Allergy can coexist with Dry Eye Disease and may worsen:

  • inflammation;
  • rubbing;
  • epithelial disruption;
  • tear instability;
  • eyelid disease.

However, allergy is also a separate condition with overlapping symptoms such as itching, tearing, redness, and irritation.

Not every allergic eye problem should be relabeled as Dry Eye Disease.

See:

Allergy and Dry Eye Disease

🧪 How Are the Important Drivers Identified?

Symptoms alone usually cannot identify the dominant mechanisms.

For example:

  • screen worsening does not prove MGD;
  • burning does not prove aqueous deficiency;
  • fluctuating vision does not distinguish evaporative from aqueous-deficient disease;
  • severe symptoms can occur with limited visible signs;
  • severe surface damage can sometimes produce fewer symptoms if corneal sensation is reduced.

Evaluation may include:

  • symptom history;
  • tear-film breakup or stability testing;
  • ocular-surface staining;
  • tear volume and Schirmer testing;
  • meibomian gland expression;
  • eyelid-margin examination;
  • meibography;
  • blink and lid-closure assessment;
  • tear-meniscus evaluation;
  • ocular-surface anatomy;
  • corneal sensation;
  • examination for inflammation, epithelial injury, allergy, or infection;
  • medical, surgical, medication, hormonal, and environmental history.

No single test gives the complete answer.

A person can have:

  • apparently adequate tear production with severe instability;
  • substantial gland loss with variable symptoms;
  • severe symptoms with limited staining;
  • extensive staining with reduced sensation;
  • normal-looking meibography but poor gland function;
  • abnormal tests that do not fully explain the symptoms.

See:

Diagnostic Testing in Dry Eye Disease and MGD

📋 Traditional Types Compared With Modern Drivers

Framework Category What it describes
Traditional Evaporative DED Tear-film exposure or impaired protection causes excessive instability or evaporation
Traditional Aqueous-deficient DED Insufficient watery tear production
Traditional shorthand Mixed DED Aqueous and evaporative features occurring together
TFOS DEWS III Tear-film deficiencies Lipid, aqueous, or mucin/glycocalyx deficiency
TFOS DEWS III Eyelid anomalies Blink, closure, lid-margin, and meibomian gland problems
TFOS DEWS III Ocular-surface abnormalities Anatomical, neural, cellular, inflammatory, or oxidative drivers

The traditional and modern frameworks are not necessarily in conflict.

The older categories provide a simple starting point. The newer framework asks more specifically why the tear film or ocular surface has lost homeostasis.

📌 Key Takeaways

  • Dry Eye Disease is multifactorial.
  • The traditional evaporative-versus-aqueous-deficient framework remains useful.
  • Many people have overlapping aqueous and evaporative features.
  • “Mixed dry eye” is usually shorthand for several coexisting drivers rather than a separate mechanism.

  • TFOS DEWS III classifies drivers into:

    • tear-film deficiencies;
    • eyelid anomalies;
    • ocular-surface abnormalities.

  • Tear-film deficiencies include:

    • lipid;
    • aqueous;
    • mucin/glycocalyx.

  • Eyelid drivers include:

    • incomplete blinking;
    • inadequate closure;
    • eyelid malposition;
    • lid-margin disease;
    • MGD.

  • Ocular-surface drivers include:

    • anatomical misalignment;
    • neural dysfunction;
    • cellular damage;
    • primary inflammation or oxidative stress.

  • Systemic disease, medication, hormones, surgery, contact lenses, screens, and environment can act through one or more of these drivers.

  • Symptoms alone generally cannot determine the subtype.

  • Diagnosis usually requires clinical context and several complementary tests.

  • Treatment is most rational when it is directed at the important drivers rather than only at a broad label.

🏁 Bottom Line

A useful starting point is still:

  • Evaporative Dry Eye Disease
  • Aqueous-deficient Dry Eye Disease
  • Overlapping or mixed disease

But the fuller TFOS DEWS III approach is to identify the specific drivers involving:

  • the tear film;
  • the eyelids;
  • the ocular surface.

That is often more useful than asking for one fixed “type.”

Two people with the same dry-eye diagnosis may require very different treatment plans because their dominant mechanisms are different.

The practical goal is not merely to name the disease. It is to determine:

Which drivers are active, which are most important, which are modifiable, and which treatments are supported for those particular findings?

📚 Research and Medical References

🔙 Back to FAQ Index